Moderna Posts Large Q3 Loss With Weaker Vaccine Demand, Projects $4B in Sales for 2024, Investors Concerned

Moderna's Q3 loss of $3.6 billion prompts reduction in manufacturing and revised 2023 sales guidance, with a recovery expected by 2025 thanks to future vaccine prospects and the company's shift towards non-COVID products.